After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Stock Information for Niagen Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Niagen Bioscience Inc.

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
The $13 Million Company Teaching the Immune System to Hunt Cancer
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.